GSK says respiratory vaccine shows 'significant' efficacy in trial
(Sharecast News) - GlaxoSmithKline said its vaccine for respiratory virus had shown "statistically significant" and clinically meaningful efficacy in adults aged 60 years and above in a phase 3 trial.
Read more